News & Updates
Filter by Specialty:
No apparent link between COVID-19 vax and cerebrovascular outcomes
Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.
No apparent link between COVID-19 vax and cerebrovascular outcomes
13 May 2022
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.
Adding canakinumab to SoC confers no survival benefit in advanced NSCLC
10 May 2022
First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.
First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
06 May 2022
Newer fixed-dose ICS/LABA combos tied to greater adherence, less exacerbations in asthma
Among fixed-dose combinations of inhaled corticosteroids/long-acting beta-2-adrenergic agonists (ICS/LABA), the newer combinations of fluticasone furoate/vilanterol (FF/VI) and fluticasone propionate/formoterol (FP/FORM) are associated with increased treatment persistence and lead to fewer exacerbations among patients with asthma, as shown in a study.
